Virchows Archiv names palisading adenocarcinoma

Salivary gland pathology is one of those fields where a new name is not just taxonomy trivia. It changes what pathologists look for, what they call a tumor, and sometimes how aggressively a case gets worked up. That is the point of the new Virchows Archiv review published on April 25, 2026 — it rounds up the salivary-gland tumor developments that landed after the WHO’s 2024 head-and-neck classification, and palisading adenocarcinoma is on that short list of emerging entities. (link.springer.com) ### What happened here? The actual news is not that a single new case appeared this week. It is that Virchows Archiv treated palisading adenocarcinoma as part of the important post-WHO update set — alongside a few other newly proposed salivary tumors — which is a signal to practicing pathologists that this is no longer an odd one-off curiosity. (link.springer.com) ### What is palisading adenocarcinoma? Basically, it is a newly described low-grade salivary gland malignancy with a very distinctive look under the microscope. The tumor shows two cell populations — a dominant group of polygonal cells arranged in trabeculae and pseudo-rosette-like patterns, plus scattered duct-forming cells, sometimes with mucocytes. That combination is the visual hook. (link.springer.com) ### Why was it easy to miss before? Because it looks like other things. The dominant cell population can read as neuroendocrine-like, and the immunostain profile adds to that confusion — strong CD56 positivity, but without the full set of classic neuroendocrine markers. On cytology, at least one recent parotid case even resembled pleomor(link.springer.com)n slot it into the wrong bucket. (link.springer.com) ### Where does it usually show up? Early reports pointed mostly to the sublingual gland, with additional submandibular cases. That was the original pattern. But the picture widened fast. A 2025 familial cohort added 18 new cases and found parotid involvement was actually the most common site in that family, and a 2026 case report described the first published parotid-gland example in a 44-year-old woman. (link.springer.com) ### How much evidence is there now? Still not a lot by common-cancer standards — but much more than there was two years ago. The 2024 Head and Neck Pathology paper helped validate the phenotype with another institutional case. The 2025 familial series said it effectively doubled the published experience. And the 2026 review in Virchows A(link.springer.com)k. (link.springer.com) ### Is this officially a WHO entity now? Not quite. The Virchows Archiv review is explicit that it covers developments from 2022 to 2025 that were not included in the WHO 2024 book. So palisading adenocarcinoma sits in that in-between zone — recognized enough to discuss seriously, but still evolving as evidence accumulates. (link.spring([link.springer.com) the biggest unresolved question? Genetics. The morphology is becoming clearer, but the molecular driver is not. The familial cohort is especially intriguing because inherited clustering is rare in salivary gland neoplasms, yet whole-exome sequencing in two cases did not reveal a recurrent alteration. That means the “why does this tumor happen?” part is still open. (link.springer.com) ### So why should anyone outside pathology care? Because classification is how cancer care starts. If a lesion gets mislabeled as a neuroendocrine neoplasm, pleomorphic adenoma, or some other salivary tumor, the clinical conversation starts from the wrong premise. New names can sound academic, but they are really error-correction tools. (link.springer.com) The bottom line is simple. Virchows Archiv did not “discover” palisading adenocarcinoma this week. It did something almost as important — it elevated the tumor into the current diagnostic conversation, which is usually how a rare entity goes from obscure paper to real-world recognition. (link.springer.com)